Literature DB >> 23463364

Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection.

Jens Martin Werner1, Theo Heller, Ann Marie Gordon, Arlene Sheets, Averell H Sherker, Ellen Kessler, Kathleen S Bean, M'Lou Stevens, James Schmitt, Barbara Rehermann.   

Abstract

UNLABELLED: Hepatitis C virus (HCV) infection typically results in chronic disease with HCV outpacing antiviral immune responses. Here we asked whether innate immune responses are induced in healthcare workers who are exposed to small amounts of HCV, but do not develop systemic infection and acute liver disease. Twelve healthcare workers with accidental percutaneous exposure to HCV-infected blood were prospectively studied for up to 6 months for phenotype and function of natural killer T (NKT) and NK cells, kinetics of serum chemokines, and vigor and specificity of HCV-specific T-cell responses. Eleven healthcare workers tested negative for HCV RNA and HCV antibodies. All but one of these aviremic cases displayed NKT cell activation, increased serum chemokines levels, and NK cell responses with increased CD122, NKp44, NKp46, and NKG2A expression, cytotoxicity (as determined by TRAIL and CD107a expression), and interferon-gamma (IFN-γ) production. This multifunctional NK cell response appeared a month earlier than in the one healthcare worker who developed high-level viremia, and it differed from the impaired IFN-γ production, which is typical for NK cells in chronic HCV infection. The magnitude of NKT cell activation and NK cell cytotoxicity correlated with the magnitude of the subsequent HCV-specific T-cell response. T-cell responses targeted nonstructural HCV sequences that require translation of viral RNA, which suggests that transient or locally contained HCV replication occurred without detectable systemic viremia.
CONCLUSION: Exposure to small amounts of HCV induces innate immune responses, which correlate with the subsequent HCV-specific T-cell response and may contribute to antiviral immunity.
Copyright © 2013 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23463364      PMCID: PMC3688637          DOI: 10.1002/hep.26353

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  33 in total

1.  Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees.

Authors:  Mohamed Tarek Shata; Nancy Tricoche; Marion Perkus; Darley Tom; Betsy Brotman; Patricia McCormack; Wolfram Pfahler; Dong-Hun Lee; Leslie H Tobler; Michael Busch; Alfred M Prince
Journal:  Virology       Date:  2003-09-30       Impact factor: 3.616

2.  Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens.

Authors:  Diego Tosi; Roberta Valenti; Agata Cova; Gloria Sovena; Veronica Huber; Lorenzo Pilla; Flavio Arienti; Filippo Belardelli; Giorgio Parmiani; Licia Rivoltini
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

3.  Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers.

Authors:  G De Carli; V Puro; G Ippolito
Journal:  Infection       Date:  2003-12       Impact factor: 3.553

4.  Targeting of human dendritic cells by autologous NK cells.

Authors:  J L Wilson; L C Heffler; J Charo; A Scheynius; M T Bejarano; H G Ljunggren
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

5.  Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines.

Authors:  Damien Sène; Franck Levasseur; Michal Abel; Marion Lambert; Xavier Camous; Céline Hernandez; Véronique Pène; Arielle R Rosenberg; Evelyne Jouvin-Marche; Patrice N Marche; Patrice Cacoub; Sophie Caillat-Zucman
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

6.  HCV persistence and immune evasion in the absence of memory T cell help.

Authors:  Arash Grakoui; Naglaa H Shoukry; David J Woollard; Jin-Hwan Han; Holly L Hanson; John Ghrayeb; Krishna K Murthy; Charles M Rice; Christopher M Walker
Journal:  Science       Date:  2003-10-24       Impact factor: 47.728

7.  Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells.

Authors:  Emanuele Durante-Mangoni; RuoJie Wang; Angela Shaulov; Qi He; Imad Nasser; Nezam Afdhal; Margaret J Koziel; Mark A Exley
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

8.  Effects of antiviral therapy on the cellular immune response in acute hepatitis C.

Authors:  Fareed Rahman; Theo Heller; Yuji Sobao; Eishiro Mizukoshi; Michelina Nascimbeni; Harvey Alter; Steven Herrine; Jay Hoofnagle; T Jake Liang; Barbara Rehermann
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

9.  Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells.

Authors:  Guido Ferlazzo; Ming L Tsang; Lorenzo Moretta; Giovanni Melioli; Ralph M Steinman; Christian Münz
Journal:  J Exp Med       Date:  2002-02-04       Impact factor: 14.307

10.  Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection.

Authors:  Naglaa H Shoukry; Arash Grakoui; Michael Houghton; David Y Chien; John Ghrayeb; Keith A Reimann; Christopher M Walker
Journal:  J Exp Med       Date:  2003-06-16       Impact factor: 14.307

View more
  32 in total

Review 1.  NKT cells in liver diseases.

Authors:  Shasha Zhu; Huimin Zhang; Li Bai
Journal:  Front Med       Date:  2018-04-06       Impact factor: 4.592

2.  Hepatic immunopathology during occult hepacivirus re-infection.

Authors:  Cordelia Manickam; Amanda J Martinot; Rhianna A Jones; Valerie Varner; R Keith Reeves
Journal:  Virology       Date:  2017-09-13       Impact factor: 3.616

3.  Acute Liver Damage Associated with Innate Immune Activation in a Small Nonhuman Primate Model of Hepacivirus Infection.

Authors:  Cordelia Manickam; Premeela Rajakumar; Lynn Wachtman; Joshua A Kramer; Amanda J Martinot; Valerie Varner; Luis D Giavedoni; R Keith Reeves
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

4.  Postexposure prophylactic effect of hepatitis B virus (HBV)-active antiretroviral therapy against HBV infection.

Authors:  Tsunamasa Watanabe; Susumu Hamada-Tsutsumi; Yoshiyuki Yokomaku; Junji Imamura; Wataru Sugiura; Yasuhito Tanaka
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

Review 5.  Natural killer cells in hepatitis C: Current progress.

Authors:  Joo Chun Yoon; Chang Mo Yang; Youkyong Song; Jae Myun Lee
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

Review 6.  Immune responses and immunopathology in acute and chronic viral hepatitis.

Authors:  Eui-Cheol Shin; Pil Soo Sung; Su-Hyung Park
Journal:  Nat Rev Immunol       Date:  2016-07-04       Impact factor: 53.106

Review 7.  Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C.

Authors:  Ulrich Spengler; Hans Dieter Nischalke; Jacob Nattermann; Christian P Strassburg
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

Review 8.  Therapeutic applications of TRAIL receptor agonists in cancer and beyond.

Authors:  Gustavo P Amarante-Mendes; Thomas S Griffith
Journal:  Pharmacol Ther       Date:  2015-09-05       Impact factor: 12.310

9.  Sustained hyperresponsiveness of dendritic cells is associated with spontaneous resolution of acute hepatitis C.

Authors:  Sandy Pelletier; Nathalie Bédard; Elias Said; Petronela Ancuta; Julie Bruneau; Naglaa H Shoukry
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

Review 10.  Natural killer cells: multifaceted players with key roles in hepatitis C immunity.

Authors:  Lucy Golden-Mason; Hugo R Rosen
Journal:  Immunol Rev       Date:  2013-09       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.